Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Outlook

Thelansis’s “Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Overview

Individuals with non-small cell lung cancer (NSCLC) who possess an epidermal growth factor receptor (EGFR) mutation constitute a distinct subgroup. The etiology, clinicopathological characteristics, prognosis, and treatment approaches of this cancer differ from those of other NSCLC patients. EGFR mutations are present in 40%–60% of Southeast Asian patients and 10%–20% of Caucasian patients with lung adenocarcinomas. While most EGFR mutation-positive tumors are found in non-smokers or light smokers, this observation is not exclusive. The rising prevalence of non-smoking behavior has led to a higher incidence of EGFR mutations in female patients compared to male patients. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non- or never-smoking lung adenocarcinoma patients, 80% of subjects were female, and 60% of tumors harbored EGFR mutations.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034